# Spark Therapeutics

临床管线 — 加速试验.

Source: https://cn.bioecon.ru/companies/spark-therapeutics/
Updated: 2026-07-02

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 初始融资$50 million | https://www.prnewswire.com/news-releases/spark-therapeutics-launched-with-50-million-in-financing-to-advance-late--and-mid-stage-gene-therapy-programs-with-clinical-proof-of-concept-228752221.html |
| 产能 | 在建500,000平方英尺基因治疗创新中心 | https://www.pharmaceutical-technology.com/projects/spark-therapeutics-gene-therapy-innovation-center-philadelphia-usa/ |
| 认证 | 生产设施持有现行良好生产规范(cGMP)认证 | https://sparktx.com/uploads/Spark-Therapeutics-Corporate-Fact-Sheet_N-SPK-US-420038-6.pdf |
| 监管批准 | LUXTURNA（voretigene neparvovec）于2017年获得 FDA 批准，用于治疗 RPE65 突变相关视网膜营养不良 | https://sparktx.com/uploads/Spark-Therapeutics-Corporate-Fact-Sheet_N-SPK-US-420038-6.pdf, https://www.sec.gov/Archives/edgar/data/1609351/000160935117000114/spark-201793010xq.htm, https://www.sec.gov/Archives/edgar/data/1609351/000160935118000072/spark-201863010xq.htm |
| 生产基地 | 宾夕法尼亚州费城（现有设施及在建的新基因治疗创新中心） | https://sparktx.com/uploads/Spark-Therapeutics-Corporate-Fact-Sheet_N-SPK-US-420038-6.pdf, https://www.pharmaceutical-technology.com/projects/spark-therapeutics-gene-therapy-innovation-center-philadelphia-usa/ |

独立来源: pharmaceutical-technology.com, prnewswire.com, sec.gov, sparktx.com

## 技术

- [体内基因治疗：AAV与慢病毒载体](https://cn.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/)